Look back at pharma news in the week to March 6, 2020
By Barbara Obstoj-Cardwell. Editor
US biotech Gilead Sciences stepped further into the immuno-oncology arena last week, announcing a $4.9 billion acquisition of Forty Seven Inc and its candidate magrolimab. On the regulatory front, Sanofi received US Food and Drug Administration for its multiple sclerosis drug Sarclisa isatuximab on Monday, some eight weeks earlier than expected. There was much reporting of developments on the novel coronavirus COVID-19, with Japan’s Takeda announcing a different approach to tackling the epidemic with plasma-based therapies via a candidate vaccine dubbed TAK-888. Also regarding research, there was disappointment for AstraZeneca, when its immune-oncology drug Imfinzi failed endpoints in a Phase III bladder cancer drug.
Gilead breaks M&A lull with ~$5 billion immuno-oncology deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze